Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Leases (2016 - 2024)

Niagen Bioscience (NAGE) has disclosed Capital Leases for 12 consecutive years, with $2000.0 as the latest value for Q3 2024.

  • Quarterly Capital Leases fell 85.71% to $2000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Sep 2024, down 85.71% year-over-year, with the annual reading at $12000.0 for FY2023, 45.45% down from the prior year.
  • Capital Leases for Q3 2024 was $2000.0 at Niagen Bioscience, down from $6000.0 in the prior quarter.
  • The five-year high for Capital Leases was $36000.0 in Q1 2020, with the low at $2000.0 in Q3 2024.
  • Average Capital Leases over 5 years is $16076.9, with a median of $14000.0 recorded in 2023.
  • The sharpest move saw Capital Leases grew 11.11% in 2020, then tumbled 85.71% in 2024.
  • Over 5 years, Capital Leases stood at $20000.0 in 2020, then tumbled by 45.0% to $11000.0 in 2021, then soared by 100.0% to $22000.0 in 2022, then plummeted by 45.45% to $12000.0 in 2023, then crashed by 83.33% to $2000.0 in 2024.
  • According to Business Quant data, Capital Leases over the past three periods came in at $2000.0, $6000.0, and $9000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.